Home › Trials › NCT06671483

Testing Zasocitinib for Psoriatic Arthritis in Adults

A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naïve to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001)

Phase 3 Interventional Takeda · NCT06671483

This study is testing a new medication called zasocitinib to see if it can help adults with active psoriatic arthritis who haven't tried biologic treatments before.

Quick facts

PhasePhase 3
Study typeInterventional
Enrollment1088 (estimated)
Ages18 Years and up
SexAll
SponsorTakeda Industry-sponsored
Drugs / interventionszasocitinib
Locations189 sites (Chandler, Arizona and 188 other locations)
Trial IDNCT06671483 on ClinicalTrials.gov

What this trial studies

This study evaluates the effectiveness of zasocitinib (TAK-279) in adults with active psoriatic arthritis (PsA) who have not previously received biologic treatments. Participants will be randomly assigned to receive either zasocitinib, an active comparator, or a placebo for up to 60 weeks. The study aims to assess improvements in joint and skin symptoms associated with PsA. Inclusion criteria include having active arthritis and meeting specific classification criteria for PsA.

Who should consider this trial

Good fit: Ideal candidates are adults aged 18 years or older with active psoriatic arthritis and a history of inadequate response to NSAIDs or conventional DMARDs.

Not a fit: Patients who have previously been treated with biologic disease-modifying antirheumatic drugs may not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment could provide a new therapeutic option for patients with psoriatic arthritis who have not responded to traditional therapies.

How similar studies have performed: Other studies have shown promise with similar drug therapies for psoriatic arthritis, indicating potential for success in this approach.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

Age:

1. The participant is aged 18 years or older at the time of signing the informed consent form (ICF). In South Korea, the age requirement for adult participants is \>=19 years of age.

   Disease Characteristics:
2. The participant has a diagnosis of PsA.
3. The participant must have signs and symptoms of PsA for at least 3 months prior to screening.
4. The participant meets the Classification Criteria for Psoriatic Arthritis (CASPAR criteria).
5. The participant has active arthritis as shown by a minimum of \>=3 tender joints in TJC68 and \>=3 swollen joints in SJC66 at the screening and baseline (Day 1) visits.
6. The participant has at least 1 active lesion of plaque PsO \>=2 cm in diameter, or any nail or nail bed changes characteristic of PsO.

   Medications for PsA:
7. The participant has had at least one of the following:

   1. Inadequate response to a nonsteroidal anti-inflammatory drug (NSAID) (not applicable in the European Union \[EU\]/ European Economic Area \[EEA\]), OR
   2. Inadequate response to a conventional synthetic disease-modifying antirheumatic drug (csDMARD).

Exclusion Criteria:

PsA and PsO:

1. The participant has other disease(s) that might confound the evaluations of benefit of zasocitinib therapy, including but not limited to rheumatoid arthritis, axial spondyloarthritis, systemic lupus erythematosus, Lyme disease, gout, or fibromyalgia.
2. The participant has a concomitant comorbid skin condition that, in the opinion of the investigator, would interfere with the study assessments, such as evidence of non-plaque PsO (erythrodermic, pustular, predominately guttate PsO, inverse, or drug-induced PsO).

Where this trial is running

Chandler, Arizona and 188 other locations

+139 more sites — see ClinicalTrials.gov for the full list.

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Psoriatic ArthritisDrug TherapyLatitude Research ProgramLatitude PsALatitude PsA-3001
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.